BNP Paribas Financial Markets
AQST icon

BNP Paribas Financial Markets’s Aquestive Therapeutics AQST Stock Holding History

BNP Paribas Financial Markets’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.31M Sell
794,688
-14,319
-2% -$60.3K ﹤0.01% 2440
2026
Q1 		$3.36M Sell
809,007
-362,668
-31% -$1.47M ﹤0.01% 2324
2025
Q4 		$7.57M Buy
1,171,675
+1,153,175
+6,233% +$7.19M ﹤0.01% 1778
2025
Q3 		$103K Buy
18,500
+9,087
+97% +$39.3K ﹤0.01% 4283
2025
Q2 		$31.2K Buy
9,413
+4,134
+78% +$11.9K ﹤0.01% 4425
2025
Q1 		$15.3K Sell
5,279
-6,261
-54% -$19K ﹤0.01% 4606
2024
Q4 		$41.1K Sell
11,540
-7,286
-39% -$33.6K ﹤0.01% 4505
2024
Q3 		$93.8K Buy
18,826
+13,481
+252% +$52.5K ﹤0.01% 3479
2024
Q2 		$13.9K Buy
5,345
+5,344
+534,400% +$17.9K ﹤0.01% 3691
2024
Q1 		$4 Hold
1
– – ﹤0.01% 4018
2023
Q4 		$2 Hold
1
– – ﹤0.01% 3996
2023
Q3 		$2 Buy
+1
New +$2 ﹤0.01% 3906
2022
Q3 		– Sell
-1,136
Closed -$727 – 4740
2022
Q2 		$727 Sell
1,136
-33,674
-97% -$44.8K ﹤0.01% 3930
2022
Q1 		$90.9K Buy
34,810
+18,860
+118% +$55.1K ﹤0.01% 3384
2021
Q4 		$62K Buy
15,950
+15,833
+13,532% +$79.5K ﹤0.01% 3699
2021
Q3 		$510 Sell
117
-104
-47% -$408 ﹤0.01% 3923
2021
Q2 		$877 Sell
221
-2,274
-91% -$9.08K ﹤0.01% 3955
2021
Q1 		$13K Sell
2,495
-868
-26% -$4.62K ﹤0.01% 3810
2020
Q4 		$18K Sell
3,363
-887
-21% -$5.32K ﹤0.01% 3861
2020
Q3 		$20.6K Buy
4,250
+3,506
+471% +$22.9K ﹤0.01% 3823
2020
Q2 		$3.62K Buy
744
+699
+1,553% +$3.22K ﹤0.01% 4107
2020
Q1 		$99 Hold
45
– – ﹤0.01% 4218
2019
Q4 		$262 Sell
45
-1,354
-97% -$7.04K ﹤0.01% 4294
2019
Q3 		$4.45K Hold
1,399
– – ﹤0.01% 4286
2019
Q2 		$5.88K Sell
1,399
-1,090
-44% -$5.58K ﹤0.01% 4217
2019
Q1 		$17.2K Buy
+2,489
New +$17.4K ﹤0.01% 3938

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BNP Paribas Financial Markets's AQST Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Aquestive Therapeutics (AQST) stake by 1.8% in Q2 2026, selling an estimated $60.3K and leaving 794,688 shares worth $3.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2440.

BNP Paribas Financial Markets first reported a position in AQST in Q1 2019 and has held it in 26 quarters since. The position peaked at $7.57M in Q4 2025. 173 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • BNP Paribas Financial Markets held 794,688 shares of Aquestive Therapeutics worth $3.31M as of Q2 2026.
  • BNP Paribas Financial Markets sold 14,319 Aquestive Therapeutics shares in Q2 2026, an estimated $60.3K.
  • Aquestive Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2440 holding.
  • BNP Paribas Financial Markets first reported a position in Aquestive Therapeutics in Q1 2019 and has held it in 26 quarters since.
  • BNP Paribas Financial Markets's Aquestive Therapeutics position peaked at $7.57M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.